[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nitric-oxide\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nitric-oxide":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,82,112,149],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100606197","evaluation-of-adding-nitrate-into-foods-for-regulating-nitric-oxide-bioavailability-in-healthy-individuals-100606197",false,"NCT07172425","Evaluation of Adding Nitrate Into Foods for Regulating Nitric Oxide Bioavailability in Healthy Individuals","An Open-Label, Randomised, Crossover Study to Investigate the Feasibility of Nitrate Fortification in Commonly Consumed Foods for Regulating Nitric Oxide Metabolism in Healthy Individuals","Inclusion Criteria:\n\n1. Healthy volunteer.\n2. Aged ≥18 years and ≤ 60 years.\n3. Willing to provide informed consent.\n4. Able to understand and comply with protocol requirements, instructions, and stated restrictions.\n\nExclusion Criteria:\n\nA volunteer will not be eligible for inclusion in this study if any of the following criteria are met:\n\n1. Unwilling to provide consent.\n2. People with chronic health conditions requiring medication.\n3. Pregnant females, or those with a possibility of being pregnant.\n4. History of hypertension and \u002For diabetes.\n5. History of any serious illnesses, including recent infections or trauma.\n6. History of symptomatic coronary artery disease, stroke, or other known atherosclerotic diseases.\n7. People who will commence or who are likely to commence treatment with non-steroidal anti-inflammatory drugs (NSAIDs) other than aspirin, from screening until study completion.\n8. Self-declared alcohol or drug abuse within the past 6 months.\n9. Three-month prior history of regular alcohol consumption exceeding an average weekly intake of \\> 28 units (or an average daily intake of greater than 3 units) for males, or an average weekly intake of \\> 21 units (or an average daily intake of greater than 2 units) for females. One unit is equivalent to a half pint (284mL) of beer\u002Flager; 25mL of spirits, or 125mL of wine.\n10. Taking systemic medication (other than the oral contraceptive pill).\n11. Recent (within 2 weeks) self-reported use of mouthwash or tongue scrapers.\n12. Recent (within 2 weeks) or current antibiotic use.\n13. Recent (within 1 week) use of NO3- or NO2- supplements.\n14. History, or recent treatment of (within the last 3 months) for any oral condition (excluding caries), including gingivitis, periodontitis and halitosis.\n15. History of, or recent treatment for, any blood-borne infectious disease such Hepatitis B or C virus, or HIV.\n16. Current smokers (including vaping) or have smoked within the last 6 months.\n17. Diagnosis of rheumatoid arthritis, connective tissue disorders, and other conditions known to be associated with chronic inflammation (e.g., Inflammatory Bowel Disease).\n18. People who have donated more than 500mL of blood within 56 days prior to the study commencement.\n19. Known allergy to celery, gluten, crustaceans, eggs, lupin, milk, mustard, peanuts, sesame, soybeans, tree nuts, oats, palm oil, sugar, cranberries, sunflower oil, invert syrup, sodium bicarbonate.",true,"ALL","18 Years","60 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"NA","Inorganic nitrate, found in leafy green vegetables and beetroot, can help lower blood pressure and support heart health. Early experimental work has suggested that dietary nitrate supplementation, in the form of beetroot juice or potassium nitrate capsules, can reduce blood pressure and improve endothelial function. Consequently, concentrated nitrate supplements like beetroot juice have become popular. However, these supplements can be expensive, high in sugar, and not to everyone's taste. Since more than three-quarters of adults with high blood pressure live in low- and middle-income countries, it is important to find safe, affordable ways to add nitrate to commonly eaten foods.\n\nThe team at Queen Mary University of London has been developing nitrate-fortified products that may be more appealing to a wider population. With support from the food manufacturer Reading Scientific Services Ltd. (RSSL), they have successfully added nitrate to three oat-based products: cereal bar, porridge, and biscuits.\n\nThis study aims to explore whether adding nitrate to commonly eaten foods can improve nitric oxide levels in the body and help lower blood pressure in healthy volunteers. Participants will receive the three nitrate-fortified food products in a randomised, crossover design. Nitrate and nitrite concentrations in biological samples, along with blood pressure, will be measured before and at multiple time points after supplementation with the nitrate-fortified products.",[28,29,30],"Healthy Volunteers","Nitric Oxide","Vascular Function",[32,33,34,35],"Blood pressure","Oral microbiome profiling","Nitric oxide bioavailability","Inorganic nitrate fortification","RECRUITING","2026-06-03",{"date":39,"type":40},"2026-06-04","ACTUAL",{"date":42,"type":40},"2025-10-15",{"date":44,"type":22},"2027-02",{"name":46,"class":47},"Queen Mary University of London","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100570077","phase-3-nitric-oxide-for-reduced-intensive-support-in-cardiac-surgery-with-cardiopulmonary-bypass-100570077","NCT06702553","Nitric Oxide for Reduced Intensive Support in Cardiac Surgery With Cardiopulmonary Bypass","Effect of Inhaled Nitric Oxide on Major Adverse Events Requiring Intensive Life Support in Adults Undergoing Cardiac Surgery With Cardiopulmonary Bypass: A Phase III, Double-Blind, Multicenter, Randomized Controlled Trial (Nitric Oxide for Reduced Intensive Support in Cardiac Surgery With Cardiopulmonary Bypass, the NORISC Trial)","NORISC","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Elective cardiac or aortic surgery requiring CPB\n3. Without history of previous open heart surgery.\n\nExclusion Criteria:\n\n1. Immediate emergency cardiac surgery;\n2. Cardiac surgery that requires deep hypothermic circulatory arrest;\n3. Planned cardiac surgery for congenital heart disease repair;\n4. Planned for heart transplatation\n5. Ongoing heart failure or low output syndrome already on intensive support (IABP, ECMO, left ventricular assist device such as impella, mechanical ventilation), left ventricular ejection fraction of \\\u003C 30% or comparable, equivalent preoperative conditions\n6. Already accepted or currently on inhaled NO therapy or inhaled\u002Faerosolized prostacyclin in the week prior to the enrollment;\n7. Endstage kidney disease with estimated glomerular filtration rate (eGFR) \\\u003C 15 ml\u002Fmin or already on renal replacement surgery.\n8. Hemophilia A or B\n9. Other terminal stage of chronic disease with life expectancy less than 1 year per evaluation and adjudication of the attending physicians.",{"count":58,"type":22},3650,[60],"PHASE3","Cardiac surgery is a procedure that is commonly performed worldwide. Despite these technological advances, cardiac surgery remains a high-risk surgery. Among post-operative complications, acute kidney injury, respiratory failure, myocardial infarction, and stroke as well as cognitive dysfunction are significant causes of mortality in patients undergoing and following cardiac surgery. Inhaled nitric oxide (NO) therapy as a selective pulmonary vasodilator in cardiac surgery has been one of the most significant pharmacological advances in managing pulmonary hemodynamics and life threatening right ventricular dysfunction and failure. In addition, newer applications show greater promise of inhaled NO as a therapy in the area of cardiac surgery associated acute kidney injury and ischemia reperfusion. However, this remarkable expectation to inhaled NO has experienced a roller-coaster ride with high hopes and nearly universal demonstration of physiological benefits but disappointing translation of these benefits to harder clinical outcomes, like mortality. Most of our understanding on the iNO field in cardiac surgery stems from small observational or single center randomized trials, which failed to ascertain strong evidence base. As a consequence, there are only week clinical practice guidelines on the field and only European expert opinion for the use of iNO in routine and more specialized cardiac surgery. There is need for a large multicenter randomized controlled study to confirm the administration of iNO as an effective weapon for the battle against life threatening complication in high risk cardiac surgical patients.\n\nIn a previous meta analysis with 27 studies included, we demonstrated that inhaled nitric oxide (NO) could reduce the duration of mechanical ventilation and reducing biomarkers of organ injury and clinical signs of organ dysfunction in cardiac surgery under cardiopulmonary bypass (CPB) , but had no significance in the ICU stay, hospital stay, and mortality. This may be attributed to the small sample size of the most included studies (of the 27 studies included, 20 studies with sample size less than 100) and heterogeneity in timing, dosage and duration of iNO administration. Well-designed, large-scale, multicenter clinical trials are needed to further explore the effect of iNO in improving postoperative prognosis in cardiovascular surgical patients.\n\nWe are planning a large multicenter controlled randomized trial to demonstrate that inhaled nitric oxide can reduce composite outcome of death and Major Adverse Events (MAEs), including need for intensive supports due to heart failure, low cardiac output sydrome, or renal failure, respiratory failure, etc., and myocardial infarction, stroke, and sepsis at 30 days after surgery from 20% to 16% in patient undergoing cardiac surgery with cardiopulmonary bypass.\n\nIf the hypothesis had been proved and validated, the results of this study can provide strong evidence for guidelines to facilitate the routine use of iNO in all cardiopulmonary bypass assisted cardiac procedures with 31,800 postoperative outcomes improved per year in US and in China.",[29,63,64,65],"Cardiac Surgery","Cardiopulmonary Bypass","Adult Patients Undergoing Cardiovascular Surgery With Cardiopulmonary Bypass",[29,67,68,69,70,71],"cardiopulmonary bypass","major adverse events","cardiac surgery","complications","Organ protection","2026-05-26",{"date":74,"type":40},"2026-05-29",{"date":76,"type":40},"2025-05-19",{"date":78,"type":22},"2029-03-31",{"name":80,"class":47},"Xijing Hospital",3,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":23,"phases":91,"briefSummary":92,"conditions":93,"keywords":97,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":48},"100567994","inhaled-nitric-oxide-in-severe-obesity-100567994","NCT06675435","Inhaled Nitric Oxide in Severe Obesity","The Effect of Inhaled Nitric Oxide on Intrapulmonary Shunt in Acutely Hypoxemic Patients With Severe Obesity","For participants with acute hypoxemic respiratory failure\n\nInclusion Criteria:\n\n* Acute hypoxemic respiratory failure, defined as persistent hypoxemia (PaO2\u002FFiO2 ≤ 300 mmHg or SpO2\u002FFiO2 ≤ 315) and on invasive mechanical ventilation for \\\u003C 72 hours\n* Presence of an arterial and central venous catheter (for blood gas measurement)\n* Admitted to a participating MGH ICU\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Pregnancy or known active breastfeeding\n* Prisoner or Incarceration\n* Inability or unwillingness of subject or legal surrogate\u002Frepresentative to give written informed consent\n* Use of inhaled or oral pulmonary vasodilatory therapy within the 24 hours preceding study enrollment\n* Contraindication to inhaled NO\n\n  * Baseline Methemoglobin ≥ 3%\n  * Known left ventricle ejection fraction \\\u003C 20%\n  * Known history of G6PD deficiency or cytochrome issues\n  * Prior adverse reaction to inhaled nitric oxide\n* Presence of pneumothorax or acute pulmonary embolism\n* Chronic hypoxemia requiring home supplemental non-invasive oxygen (nasal cannula or positive pressure ventilation) or home mechanical ventilation\n* Chronic pulmonary vascular disease on home chemical vasodilator support (e.g., sildenafil)\n* History of lung resection or transplant\n* Hemodynamic instability at the time of potential study enrollment defined as:\n\n  * Persistent systolic blood pressure \\\u003C 90 mmHg or \\>180 mmHg despite the use of vasopressor or vasodilators or\n  * Requiring an increment in inotropic-vasopressors over the past two hours just before enrollment: more than 15 mcg\u002Fmin for norepinephrine and dopamine, more than 10 mcg\u002Fmin in epinephrine; and more than 50 mcg\u002F min for phenylephrine.\n\nEIT assessments of lung perfusion will only be performed in participants who are already receiving neuromuscular blocking agents (e.g., cisatracurium) at the time of study enrollment. EIT assessments of lung perfusion will not be performed in participants who have the following contraindications to EIT perfusion monitoring:\n\n* Hypernatremia (serum sodium \\> 150 mEq\u002FL)\n* Usage of any devices with electric current generation such as pacemaker or internal cardiac defibrillator\n\nFor controls without acute hypoxemic respiratory failure\n\nInclusion Criteria:\n\n* Receiving invasive mechanical ventilation and do not have a diagnosis of acute hypoxemic respiratory failure (PaO2\u002FFiO2 \\> 300 mmHg or SpO2\u002FFiO2\\> 315)\n* Presence of an arterial catheter\n* Admitted to a participating MGH ICU\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Pregnancy or known active breastfeeding\n* Prisoner or Incarceration\n* Inability or unwillingness of subject or legal surrogate\u002Frepresentative to give written informed consent",{"count":90,"type":22},60,[25],"The goal of this clinical trial is to learn about the effects of inhaled nitric oxide on oxygenation and lung perfusion in participants with severe obesity who have acute hypoxemic respiratory failure and are on mechanical ventilation\n\nThe main questions it aims to answer are:\n\n1. In acute hypoxemic respiratory failure, what are the effects of inhaled nitric oxide on oxygenation in participants with severe obesity compared to participants with normal body weight.\n2. In acute hypoxemic respiratory failure, what are the effects of inhaled nitric oxide on lung perfusion and heart function in participants with severe obesity compared to participants with normal body weight.\n3. In acute hypoxemic respiratory failure, does severe obesity impact nitric oxide signaling pathways?\n\nParticipants with acute hypoxemic respiratory failure will be exposed to inhaled nitric oxide (20 ppm) while being clinically monitored.",[94,95,96,29],"Obesity","Respiratory Insufficiency","Hypoxemic Respiratory Failure",[98,99,100,101],"severe obesity","acute hypoxemic respiratory failure","intrapulmonary shunt","inhaled nitric oxide","NOT_YET_RECRUITING","2026-05-19",{"date":105,"type":40},"2026-05-20",{"date":107,"type":22},"2026-10",{"date":109,"type":22},"2028-12",{"name":111,"class":47},"Massachusetts General Hospital",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":23,"phases":121,"briefSummary":122,"conditions":123,"keywords":129,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":48},"100567804","dose-response-impact-of-glucosyl-hesperidin-citrapeak-on-exercise-performance-blood-flow-stress-cognition-and-other-perceptual-indicators-100567804","NCT06672952","Dose-Response Impact of Glucosyl-Hesperidin (CitraPeak) on Exercise Performance, Blood Flow, Stress, Cognition, and Other Perceptual Indicators","HES","Inclusion Criteria:\n\n1. Participants who are between 18 - 50 years of age\n2. Body mass index values will range from \\>25.0 \\\u003C 30.0 kg\u002Fm2\n3. The average body mass index for entire study cohort will be less than 27.0 kg\u002Fm2. As such an ongoing calculation of the recruited cohort's mean body mass index will be maintained and people will only be randomized into the study if the average cohort body mass index value does not exceed 27.0 kg\u002Fm2\n4. Free-living and independent\n5. In good health absent of being overweight or mildly obese with no other signs or symptoms of cardiovascular, respiratory, metabolic, immune, psychiatric, or musculoskeletal disease or disorders\n6. Willingness to maintain consistent sleep duration the evening before study visits\n7. Willing and able to agree to the requirements and restrictions of this study, be willing to give voluntary consent, and carry out all study-related procedures\n8. Regular completion of at least 180 minutes of moderate to vigorous exercise per week for the past 6 months\n\nExclusion Criteria:\n\n1. Not currently completing at least 180 minutes of moderate to vigorous exercise per week for the past 6 months\n2. Positive medical history and\u002For is currently being treated for some form of heart disease, cardiovascular disease\n3. Currently being treated for kidney disease, renal failure, or has dialysis performed on regular intervals\n4. Has liver disease or some form of clinically diagnosed hepatic impairment\n5. Diagnosed with having Type I or Type II diabetes (determined as fasting blood glucose \\> 126 mg\u002FdL)\n6. Diagnosed with or is being treated for some form of thyroid disease\n7. Diagnosed with major affective disorder or other psychiatric disorder that required hospitalization in the prior year\n8. Diagnosed with some form of immune disorder (i.e., HIV\u002FAIDS)\n9. History of cancer (except localized skin cancer without metastases or in situ cervical cancer within 5 years prior to screening visit).\n10. Participant has an abnormality or obstruction of the gastrointestinal tract precluding swallowing (e.g., dysphagia) and digestion (e.g., known intestinal malabsorption, celiac disease, inflammatory bowel disease, chronic pancreatitis, steatorrhea)\n11. Positive medical history for any neurological condition or neurological disease\n12. Currently prescribed a statin drugs (i.e., Lipitor, Livalo, Crestor, Zocor, etc.) or any hypertension medications (i.e., Beta-blockers, ACE Inhibitors, Alpha blockers, Vasodilators, etc.)\n13. Current smoker (average of \\> 1 pack per day within the past 3 months) has quit within the past six months. This includes all forms of nicotine\n14. Intake of any drugs (prescribed or over the counter) or dietary supplements that are known or are purported to weight loss such as thermogenics, hydroxycitric acid, ephedra, capsaicin, etc.\n15. Participants who are lactating, pregnant or planning to become pregnant\n16. Have a known sensitivity or allergy to any of the study products\n17. History of alcohol or substance abuse in the 12 months prior to screening\n18. Receipt or use of an investigational product in another research study within 30 days of beginning the study protocol\n19. Any orthopedic limitation that would prevent participation in a general fitness program\n20. Any condition or abnormality that, in the opinion of the investigator, would compromise the safety of the participant or the quality of the study data","50 Years",{"count":90,"type":22},[25],"The purpose of this study is to evaluate the dose-dependent effects of glucosyl-hesperidin (CITRAPEAK) supplementation on exercise performance, recovery indicators, blood flow, cognitive function, mood, sleep, and fuel utilization in recreationally active adults.",[124,125,126,29,127,128],"Exercise Performance","Exercise Recovery","Cognitive Function","Blood Flow","Endurance Exercise",[130,131,132,133,134,135,136,137,138,139],"exercise performance","aerobic capacity","anaerobic power","mood","nitric oxide","cognitive function","glucosyl-hesperidin","training readiness","fuel utilization","endothelial function","2025-12-05",{"date":142,"type":40},"2025-12-12",{"date":144,"type":40},"2025-04-15",{"date":146,"type":22},"2026-01-01",{"name":148,"class":47},"Lindenwood University",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":17,"minAge":119,"maxAge":4,"enrollmentInfo":157,"targetDuration":4,"studyType":23,"phases":159,"briefSummary":161,"conditions":162,"keywords":166,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":179},"100566653","phase-2-response-to-exercise-and-nitric-oxide-in-pad-100566653","NCT06657976","Response to Exercise and Nitric Oxide in PAD","Response to Exercise and Nitric Oxide in Peripheral Artery Disease: The RESIST PAD Trial","RESIST","Inclusion Criteria:\n\n1. An ABI less than or equal to 0.90 at baseline.\n2. Vascular lab evidence of PAD (such as a toe brachial pressure less than or equal to 0.70 or an ankle brachial index less than or equal to 0.90), or angiographic evidence of PAD defined as at least 70% stenosis of an artery supplying the lower extremities.\n3. An ABI of more than 0.90 and less than 1.00 who experience a 20% or greater drop in ABI in either leg after the heel-rise test.\n\nExclusion Criteria:\n\n1. Above- or below-knee amputation\n2. Limb-threatening ischemia defined as an ABI less than 0.40 with symptoms of rest pain\n3. Wheelchair confinement or requiring a walker to ambulate\n4. Walking is limited by a condition other than PAD\n5. Current foot ulcer on bottom of foot\n6. Failure to complete study-run\n7. Unwilling to accept randomization into either group (supervised exercise or attention control)\n8. Planning to engage in new walking exercise outside of the study or unwilling to refrain from new walking exercise activity during the trial.\n9. Already exercising at a level consistent with exercise intervention, using investigator discretion.\n10. End-stage kidney disease (ESKD) that is treated with hemodialysis.\n11. Planned major surgery, coronary or leg revascularization during the next six months\n12. Major surgery, coronary or leg revascularization or major cardiovascular event in the previous three months\n13. Major medical illness including lung disease requiring oxygen, Parkinson's disease, a life-threatening illness with life expectancy less than six months, or cancer requiring treatment in the previous two years. \\[NOTE: potential participants may still qualify if they have had treatment for an early stage cancer in the past two years and the prognosis is excellent. Participants who require oxygen only at night may still qualify.\\]\n14. Mini-Mental Status Examination (MMSE) score less than 23 or dementia. If the MMSE is less than 23 and the Principal Investigator evaluation determines that the lower score is related to language barriers or education level, the Principal Investigator has discretion to allow a participant with MMSE less than 23 to participate, as appropriate. Dementia with sufficient impairment to prevent full engagement in all aspects of the trial will be an exclusion per the investigator's discretion.\n15. Allergy to beetroot juice\n16. Currently consuming beetroot juice, oral nitrate or nitrite, or a beetroot supplement and\u002For unwilling to avoid beetroot juice during the study. Participants will be asked to discontinue these items for 30 days before baseline testing and throughout the clinical trial. If the potential participant is unwilling to refrain from taking these items, they will not be eligible for the clinical trial.\n17. Currently consuming one cup or more of beets daily. Participants will be asked to discontinue beet ingestion of one cup or more of beets for 30 days before baseline testing and throughout the clinical trial. If the potential participant is unwilling to refrain from daily beet consumption of one cup or more for 30 days before the trial and during the trial, they will not be eligible for the clinical trial.\n18. Unstable angina\n19. Abnormal baseline stress test without subsequent clearance for exercise by physician\n20. Non-English speaking. The RESIST PAD interventions are delivered by interventionists who do not speak non-English languages. The integrity of the clinical trial requires clear and effective communication for data collection and intervention delivery. The trial does not have staff members who are fluent in non-English languages nor does it have the ability to translate all study materials into other languages.\n21. Participation in or completion of a clinical trial in the previous three months. \\[NOTE: after completing a stem cell or gene therapy intervention, participants will become eligible after the final study follow-up visit of the stem cell or gene therapy study so long as at least six months have passed since the final intervention administration. After completing a supplement or drug therapy (other than stem cell or gene therapy), participants will be eligible after the final study follow-up visit as long as at least three months have passed since the final intervention of the trial.\\] Participants in a study that involved up to three single doses of nitrate-rich beetroot juice administered on separate days may participate if a month has passed since their last dose of nitrate-rich beetroot juice.\n22. Visual impairment that limits walking ability.\n23. Baseline blood pressure less than 100\u002F45.\n24. Participation in a supervised treadmill exercise program in previous three months or planning to begin a supervised treadmill exercise program in the next six months.\n25. In addition to the above criteria, investigator discretion will be used to determine if the trial is unsafe or not a good fit for the potential participant.",{"count":158,"type":22},200,[160],"PHASE2","RESIST PAD is a randomized trial of 200 PAD patients to establish: 1) whether a 12-week exercise intervention significantly increases Δ nitrite at 12-week follow-up, compared to control; 2) whether exercise \"responders\" have greater Δ nitrite increases compared to \"non-responders\"; 3) among non-responders, whether supplementing exercise with nitrate-rich beetroot juice between weeks 13-24 increases Δ nitrite and improves 6-minute walk at 24-week follow-up.",[163,164,165,29],"Peripheral Artery Disease","Exercise","Intermittent Claudication",[167,168,169],"Peripheral artery disease","Claudication","Walking difficulty","2025-07-09",{"date":172,"type":40},"2025-07-11",{"date":174,"type":40},"2025-01-23",{"date":176,"type":22},"2029-10-01",{"name":178,"class":47},"Northwestern University",2]